Free Trial

TFF Pharmaceuticals Q1 2024 Earnings Report

TFF Pharmaceuticals logo
$0.06 0.00 (0.00%)
(As of 12/20/2024 ET)

TFF Pharmaceuticals EPS Results

Actual EPS
-$2.40
Consensus EPS
-$2.20
Beat/Miss
Missed by -$0.20
One Year Ago EPS
N/A

TFF Pharmaceuticals Revenue Results

Actual Revenue
$0.20 million
Expected Revenue
$0.15 million
Beat/Miss
Beat by +$50.00 thousand
YoY Revenue Growth
N/A

TFF Pharmaceuticals Announcement Details

Quarter
Q1 2024
Time
N/A

Conference Call Resources

Trump’s Sending THIS Crypto Higher on Purpose (Ad)

Discover the coin set to explode before 2025! Trump could trigger THIS crypto coin…

YES, I WANT THE #1 CRYPTO NOW

TFF Pharmaceuticals Earnings Headlines

Wall Street Icon: “You must get on the right side of this thing”
I created one of the first quantitative analysis-based stock picking systems long before "quants" became a thing on Wall Street… leading Forbes to call me "King of the Quants." I'm writing to you today because my system has recently uncovered a market phenomenon I haven't seen in 30 years.
TFF Pharmaceuticals terminates employees, to wind down operations
TFF Pharmaceuticals to Dissolve and Liquidate Assets
TFF Pharmaceuticals Announces It Will Wind Down Operations
See More TFF Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like TFF Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on TFF Pharmaceuticals and other key companies, straight to your email.

About TFF Pharmaceuticals

TFF Pharmaceuticals (NASDAQ:TFFP), a clinical stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform in the United States and Australia. It intends to focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions. The company's drug candidates are TFF Voriconazole Inhalation Powder, which is in Phase II clinical trials for the treatment and prophylaxis of invasive pulmonary aspergillosis; and TFF Tacrolimus Inhalation Powder, which is in Phase II clinical trials used to prevent lung transplant rejection. It also develops other dry powder products, such as Augmenta human derived monoclonal antibodies for the treatment of COVID-19 disease; and other vaccines. It has a license agreement with the University of Texas at Austin for the development of inhaled dry powder drugs. TFF Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Fort Worth, Texas.

View TFF Pharmaceuticals Profile

More Earnings Resources from MarketBeat

Upcoming Earnings